Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. (Q38036613)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22911671%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

meta-analysis

0 references

title

Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22911671%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22911671%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Lucas Vieira dos Santos

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22911671%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Fabiano Hahn Souza

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22911671%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Andre Tesainer Brunetto

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22911671%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

João Paulo da Silveira Nogueira Lima

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22911671%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

language of work or name

English

0 references

publication date

21 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22911671%20AND%20SRC:MED&resulttype=core&format=json

Journal of the National Cancer Institute

11 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22911671%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

104

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22911671%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22911671%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

1280-1292

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22911671%20AND%20SRC:MED&resulttype=core&format=json

Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics.

11 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Symptom prevalence in patients with incurable cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Predicting development of anticipatory nausea in cancer patients: prospective examination of eight clinical characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Proposal for classifying the acute emetogenicity of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Delayed emesis: incidence, pattern, prognostic factors and optimal treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Roles of substance P and NK(1) receptor in the brainstem in the development of emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Statistics notes. Units of analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chem

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Systemic neuropeptide levels as predictive indicators for lethal outcome in patients with postoperative sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Bone marrow transplantation reveals an essential synergy between neuronal and hemopoietic cell neurokinin production in pulmonary inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

The impact of substance P signalling on the development of experimental staphylococcal sepsis and arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

Meta-analysis for rare events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS335